WHO-politik fører til medicin-resistent AIDS-virus
Tech Central Station har en interessant artikel om de katastrofale følger WHO´s kampagne for at behandle millioner af 3.-verdens AIDS-patienter med billig kopi-medicin har: livsvarigt bindende udgifter og medicin-resistente AIDS-varianter. Smagsprøver:
Two recent studies should have set off alarm bells at WHO headquarters and the Global Fund. On July 15, during the 10th National AIDS Seminar in Bangkok, scientists from the faculty of medicine at Ramathibodi Hospital in the Thai capital announced that the rate of drug resistance from antiretroviral copy drugs manufactured by the Government Pharmaceutical Organization (GPO) have led to dramatic increases in drug resistance and it is expected to worsen. The GPO drug is a triple dose combination consisting of lamivudine, stavudine and nevirapine. The hospital reported the following rates of drug resistance: "lamivudine, 49 percent; stavudine, 39.6 percent; and, nevirapine at 58 percent".
Thai authorities estimated that while the price of the GPO triple dose drug is $24 per person per month, drug resistance will force patients onto second line therapies in which the price rises to $239 per month, almost a 10 fold increase. Unfortunately, this increase only covers the price of drugs. The costs of medical care treatment, such as by healthcare specialists, in-patient care, etc., have not been factored in. They can be at least three times to four times the product price.
The second study appeared in the August edition of The British Medical Journal. It reported that "resistance to antiviral drugs is climbing and evidence from research that followed 4500 British patients infected with HIV indicates that after two years of standard treatment with a combination of different classes of antiretroviral drugs 10% of people become drug resistant to at least one drug. Six years after starting treatment, 27% are resistant to at least one of their drugs".
Two recent studies should have set off alarm bells at WHO headquarters and the Global Fund. On July 15, during the 10th National AIDS Seminar in Bangkok, scientists from the faculty of medicine at Ramathibodi Hospital in the Thai capital announced that the rate of drug resistance from antiretroviral copy drugs manufactured by the Government Pharmaceutical Organization (GPO) have led to dramatic increases in drug resistance and it is expected to worsen. The GPO drug is a triple dose combination consisting of lamivudine, stavudine and nevirapine. The hospital reported the following rates of drug resistance: "lamivudine, 49 percent; stavudine, 39.6 percent; and, nevirapine at 58 percent".
Thai authorities estimated that while the price of the GPO triple dose drug is $24 per person per month, drug resistance will force patients onto second line therapies in which the price rises to $239 per month, almost a 10 fold increase. Unfortunately, this increase only covers the price of drugs. The costs of medical care treatment, such as by healthcare specialists, in-patient care, etc., have not been factored in. They can be at least three times to four times the product price.
The second study appeared in the August edition of The British Medical Journal. It reported that "resistance to antiviral drugs is climbing and evidence from research that followed 4500 British patients infected with HIV indicates that after two years of standard treatment with a combination of different classes of antiretroviral drugs 10% of people become drug resistant to at least one drug. Six years after starting treatment, 27% are resistant to at least one of their drugs".
posted by Henrik | 11:34 AM
0 Comments:
Send en kommentar
<< Home